DigeHealth secures CHF 1.25 million seed round to transform gastro-intestinal monitoring
Share this article
DigeHealth SA, a Swiss medtech company developing a wearable device that “listens to the gut” to support early detection and management of gastro-intestinal complications, announced the successful closing of a CHF 1.25 million Seed round.
The round was led by Medin Fund Management with the participation of Lichtsteiner Foundation and will enable DigeHealth to accelerate the product development, clinical validation, and regulatory approval processes. Digital Africa and Joylab SA also participated in the round, adding valuable support to DigeHealth’s continued development.
Nour Ghalia Abassi, Co-founder and CEO of DigeHealth, said: “Bowel sounds are a constant yet largely untapped source of information on our gut health. By harnessing them we can transform clinical decision-making in gastroenterology. Our ambition is to redefine gastrointestinal monitoring through advanced acoustics, sensor fusion, and artificial intelligence, creating personalised digital biomarkers that make gut health continuously measurable, objective, and actionable. We deeply value the trust placed in us by our partners, whose support strengthens our ability to bring new acoustic digital biomarkers into clinical practice and improve outcomes for patients worldwide.”
Marcel Wuethrich, Chairman of the board, added: “20 % of people on this planet suffer from gastrointestinal disorders. Efficient tools to continuously monitor disease progression and therapy success in hospital and home settings are lacking. That’s why health tech innovator Evoleen initiated the development of DigeHealth – a miniature 24/7 continuous bowel monitoring solution. The market potential is huge, and we are delighted that new investors and partners are joining our mission to make a significant contribution to the transformation of gastroenterology.”
Professor Dr. med. Daniel Pohl, Co-founder and Medical Director of DigeHealth, added: “Intestinal motility remains a medical enigma, is usually tested only for very short time spans and lacks contextual patient-symptom integration. We often simply do not understand what is going on with our patients. Having a long-standing interest both in clinics and research of chronic bowel disorders, I co-founded DigeHealth to help patients with the most diverse intestinal issues, give their bowel a digital voice and my scientific and commercial partners attain a digital biomarker of digestive disease. From life-threatening post-operative ileus to nutrition intolerance, from neurogenic bowel dysfunction to inflammatory bowel disease – we are there to make an impact.”
➡️ Source: Digehealth | 📸 ©DigeHealth. Lyle Halliday, CTO and co-founder and Nour Ghalia Abassi, Co-founder and CEO of DigeHealth.